Position history for UBS Group AG's holdings in Protagonist Therapeutics Inc
UBS Group AG holds 5.2M shares of PTGX (Protagonist Therapeutics Inc), worth $545.7M as of 2026-Q1. The position was increased (+86.9% shares). PTGX represents 0.1% of UBS Group AG's portfolio.
Current Value
$545.7M
Current Shares
5.2M
Total Value Change
+$543.4M
Total Shares Change
+5.1M
Other major holders of PTGX: BlackRock, Inc., FARALLON CAPITAL MANAGEMENT LLC
Increased |
| 5.2M |
+86.9% |
| $545.7M |
| 0.1% |
| $91.30 |
49 |
| 2025-Q4 | Increased | 2.8M | +46.1% | $241.9M | 0.0% | $87.26 | 42 |
| 2025-Q3 | Decreased | 1.9M | -24.2% | $126M | 0.0% | $65.14 | 0 |
| 2025-Q2 | Increased | 2.5M | +608.8% | $138.2M | 0.0% | $55.69 | 49 |
| 2025-Q1 | Increased | 352,871 | +166.1% | $17.1M | 0.0% | $48.88 | 46 |
| 2024-Q4 | Increased | 132,609 | +68.3% | $5.1M | 0.0% | $38.51 | 40 |
| 2024-Q3 | Increased | 78,799 | +17.6% | $3.5M | 0.0% | $44.56 | 31 |
| 2024-Q2 | Decreased | 66,981 | -62.3% | $2.3M | 0.0% | $34.65 | 0 |